Ensysce Biosciences Q1 net loss widens, cash falls sharply

Ensysce Biosciences

15/05/2026 21:32

Overview

US pain therapeutics developer's Q1 net loss widened compared to prior year

Company's cash position fell sequentially during Q1

G&A expenses were $1.2 million in Q1, compared to $1.4 million last year

Outlook

Ensysce expects continued losses for the foreseeable future as R&D efforts progress

Result Drivers

HIGHER R&D SPENDING - Increased external research and development costs related to Phase 3 clinical trial activity for PF614 drove up expenses

LOWER GRANT FUNDING - Federal grant funding fell due to timing of research activities eligible for funding under the MPAR grant

Company press release: ID:nACShFpWCa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$3.60 mln


Analyst Coverage

Wall Street's median 12-month price target for Ensysce Biosciences Inc is $16.45, about 5,834.3% above its May 14 closing price of $0.28

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)